Development of the Double-Blind, Randomized Trials of Effects of Antihypertensive Medicines (DREAM) Database and Characteristics of the Included Trials: Protocol for an Umbrella Review and Meta-Analyses
JMIR Research Protocols · 2025
DOI: 10.2196/65205 ↗At a glance
Metaanalyse in JMIR Research Protocols, 2025. Written by Abdul Salam and 16 co-authors. Institution: The George Institute for Global Health, Hyderabad, Telangana, India. Major MEDLINE topics: Antihypertensive Agents, Randomized Controlled Trials as Topic, Hypertension, Databases, Factual. Cited 1 times so far (Crossref); 25 references. The full text is freely available in PubMed Central.
Abstract (original language)
Background
A comprehensive evaluation of short-term effects of antihypertensive medicines is important for informing guidelines and clinical practice.
Objective
We aimed to develop the Double-blind Randomized trials of Effects of Antihypertensive Medicines (DREAM) database to facilitate a series of meta-analyses evaluating the short-term effects of antihypertensive medicines.
Methods
We searched the Cochrane Central Register of Controlled Trials, MEDLINE, and Epistemonikos from inception until December 2022 to identify relevant randomized clinical trials (RCTs). We included RCTs in the DREAM database if they were double-blind, enrolled adult participants, evaluated the 5 major classes of antihypertensive medicines over a duration of 2 to 26 weeks, and were published in the English language. Screening of records for inclusion and data collection were both conducted in duplicate. The planned meta-analyses using the DREAM database will follow standard methods as recommended by the Cochrane Handbook for Systematic Reviews. The general methods for these meta-analyses are outlined.
Results
The DREAM database includes 1623 RCTs (4359 comparisons), of which 44% (707/1623) were placebo-controlled, 70% (1141/1623) had parallel-group allocation, and 37% (607/1623) had 3 or more randomized groups. A total of 304,253 participants (mean age 54 years; 509/1623, 46% female) were included, 86% (1391/1623) of RCTs had participants with hypertension, and 11% (175/1623) of RCTs had participants with cardiovascular disease at baseline. RCTs with at least 1 group randomized to combination therapy accounted for 23%(371/1623). The median duration of treatment was 8 weeks. Most (93%, 1509/1623) RCTs reported data on effects on blood pressure.
Conclusions
The first series of meta-analyses using the DREAM database will assess the effects of antihypertensive medicines on blood pressure and safety outcomes, including effects on headache, and cardiovascular events. The findings of these meta-analyses will inform clinical practice guidelines and help identify priorities for future research. International Registered Report Identifier (IRRID) DERR1-10.2196/65205
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- The George Institute for Global Health, Hyderabad, Telangana, India.
- The George Institute for Global Health, University of New South Wales, Sydney, Australia.
- Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India.
- School of Medicine, Keele University, England, United Kingdom.
- The George Institute for Global Health, The George Institute for Global Health, Sydney, Australia.
- School of Public Health, The University of Adelaide, Adelaide, Australia.
ORCID profiles: Abdul Salam, Rupasvi Dhurjati, Kota Vidyasagar, Prachi Kaistha, Hariprasad Esam, Faraidoon Haghdoost, Rashmi Pant, Amit Kumar, Raju Kanukula, Rakesh Thode, Ravali Baddam, Kanika Chaudhri, Nelson Wang, Soumyadeep Bhaumik, Sonali R Gnanenthiran, Sasi Kumar Tiruttani, Anthony Rodgers
Cite
APA
Salam, A., Dhurjati, R., Vidyasagar, K., Kaistha, P., Esam, H., Haghdoost, F., Pant, R., Kumar, A., Kanukula, R., Thode, R., Baddam, R., Chaudhri, K., Wang, N., Bhaumik, S., Gnanenthiran, S. R., Tiruttani, S. K., & Rodgers, A. (2025). Development of the Double-Blind, Randomized Trials of Effects of Antihypertensive Medicines (DREAM) Database and Characteristics of the Included Trials: Protocol for an Umbrella Review and Meta-Analyses. JMIR Research Protocols. https://doi.org/10.2196/65205
Vancouver
Salam A, Dhurjati R, Vidyasagar K, Kaistha P, Esam H, Haghdoost F, et al. Development of the Double-Blind, Randomized Trials of Effects of Antihypertensive Medicines (DREAM) Database and Characteristics of the Included Trials: Protocol for an Umbrella Review and Meta-Analyses. JMIR Research Protocols. 2025. doi:10.2196/65205
BibTeX
@article{Salam2025,
author = {Salam, Abdul and Dhurjati, Rupasvi and Vidyasagar, Kota and Kaistha, Prachi and Esam, Hariprasad and Haghdoost, Faraidoon and Pant, Rashmi and Kumar, Amit and Kanukula, Raju and Thode, Rakesh and Baddam, Ravali and Chaudhri, Kanika and Wang, Nelson and Bhaumik, Soumyadeep and Gnanenthiran, Sonali R and Tiruttani, Sasi Kumar and Rodgers, Anthony},
title = {Development of the Double-Blind, Randomized Trials of Effects of Antihypertensive Medicines (DREAM) Database and Characteristics of the Included Trials: Protocol for an Umbrella Review and Meta-Analyses},
journal = {JMIR Research Protocols},
year = {2025},
doi = {10.2196/65205}
}
EUVIMED